Automate Your Wheel Strategy on NVAX
With Tiblio's Option Bot, you can configure your own wheel strategy including NVAX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowNews
Is Trending Stock Novavax, Inc. (NVAX) a Buy Now?
Published: March 03, 2026 by: Zacks Investment Research
Sentiment: Positive
Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
What's Going On With Novavax Stock On Friday?
Published: February 27, 2026 by: Benzinga
Sentiment: Neutral
Novavax Inc. (NASDAQ: NVAX) shares are down on Friday, possibly on profit-taking after the stock rallied on Thursday following the company's announcement of its fourth-quarter and full-year 2025 financial results.
Read More
Novavax: The Bear Case Is Broken, But The Bull Case Needs More Proof
Published: February 27, 2026 by: Seeking Alpha
Sentiment: Positive
Novavax (NVAX) has transitioned into a royalty-driven model, with Q4 profitability and 73% of revenue from licensing and royalties. NVAX's FY26 revenue guidance of $230M–$270M reflects cleaner, high-margin cash flow, excluding potential $200M in milestones from Sanofi. With $857M in cash and receivables, NVAX is funded into 2028, but remains highly dependent on partner outcomes, especially Sanofi's COVID/influenza program.
Read More
Novavax Stock Gains as Q4 Earnings & Sales Beat Estimates
Published: February 27, 2026 by: Zacks Investment Research
Sentiment: Positive
NVAX stock jumps 17% after Q4 swings to a surprise profit on strong licensing revenues and lower costs, with sales soaring 67% year over year.
Read More
Novavax, Inc. (NVAX) Q4 2025 Earnings Call Transcript
Published: February 26, 2026 by: Seeking Alpha
Sentiment: Neutral
Novavax, Inc. (NVAX) Q4 2025 Earnings Call Transcript
Read More
COVID-19 Vaccine Maker Novavax Swings To Profit As Sales Climb
Published: February 26, 2026 by: Benzinga
Sentiment: Positive
Novavax Inc. (NASDAQ: NVAX) shares are up on Thursday following the company's announcement of its fourth-quarter and full-year 2025 financial results.
Read More
Novavax (NVAX) Beats Q4 Earnings and Revenue Estimates
Published: February 26, 2026 by: Zacks Investment Research
Sentiment: Positive
Novavax (NVAX) came out with quarterly earnings of $0.11 per share, beating the Zacks Consensus Estimate of a loss of $0.66 per share. This compares to a loss of $0.51 per share a year ago.
Read More
Is Most-Watched Stock Novavax, Inc. (NVAX) Worth Betting on Now?
Published: February 17, 2026 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it worthwhile to examine what the stock has in store.
Read More
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know
Published: February 06, 2026 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Moderna Vs. Novavax: 2 Pandemic Vaccine Pioneers - Which Offers Better Value Today?
Published: January 30, 2026 by: Seeking Alpha
Sentiment: Neutral
Moderna, Inc. and Novavax, Inc. have transitioned from pandemic-era highs to focusing on cost reduction, pipeline development, and a path to breakeven by 2028. NVAX leverages partnerships with Sanofi and Pfizer, targeting ~$500m annual revenues by 2030, with a forward P/S of ~3x and P/E of ~7.5x. MRNA's growth depends on COVID/flu combo vaccine, intismeran cancer program, and RSV vaccine, but faces higher risk due to elevated spending and lack of major partners.
Read More
Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It
Published: January 26, 2026 by: Zacks Investment Research
Sentiment: Positive
Novavax (NVAX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
Novavax Grants License for Use of Matrix-M Adjuvant to Pfizer
Published: January 21, 2026 by: Zacks Investment Research
Sentiment: Neutral
NVAX inks a non-exclusive Matrix-M license, securing $30M upfront, up to $500M in milestones and mid-single-digit royalties from Pfizer.
Read More
Novavax Stock Pops After Pfizer Licensing Agreement
Published: January 20, 2026 by: Schaeffers Research
Sentiment: Positive
Novavax Inc. (NASDAQ:NVAX) shares are up 3.3% to trade at $8.27 at last glance, after the vaccine company singed a licensing agreement -- worth up to $500 million, including a $30 million upfront payment -- with Pfizer (PFE) for use of its Matrix-M adjuvant for up to two disease areas.
Read More
Novavax (NVAX) Moves 11.9% Higher: Will This Strength Last?
Published: January 14, 2026 by: Zacks Investment Research
Sentiment: Positive
Novavax (NVAX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Read More
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know
Published: January 13, 2026 by: Zacks Investment Research
Sentiment: Positive
Novavax (NVAX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It
Published: December 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it worthwhile to examine what the stock has in store.
Read More
Investors Heavily Search Novavax, Inc. (NVAX): Here is What You Need to Know
Published: December 19, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Here is What to Know Beyond Why Novavax, Inc. (NVAX) is a Trending Stock
Published: December 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
FDA Plans to Tighten Vaccine Approvals Weigh on These Stocks
Published: December 01, 2025 by: Investopedia
Sentiment: Neutral
A report that vaccine approvals could be set to get stricter is pressuring shares of major vaccine makers.
Read More
Vaccine stocks take a hit as FDA official points to link between COVID-19 vaccines and rare heart condition in young men
Published: December 01, 2025 by: Market Watch
Sentiment: Negative
Memo also reportedly mentions vaccines for flu and pneumonia.
Read More
Is Trending Stock Novavax, Inc. (NVAX) a Buy Now?
Published: November 25, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it worthwhile to examine what the stock has in store.
Read More
Novavax, Inc. (NVAX) Presents at Jefferies London Healthcare Conference 2025 Transcript
Published: November 19, 2025 by: Seeking Alpha
Sentiment: Neutral
Novavax, Inc. ( NVAX ) Jefferies London Healthcare Conference 2025 November 19, 2025 11:30 AM EST Company Participants Ruxandra Draghia-Akli - Executive VP and Head of Research & Development James Kelly - Executive VP, CFO & Treasurer Conference Call Participants Jiale Song - Jefferies LLC, Research Division Presentation Jiale Song Jefferies LLC, Research Division Welcome to Jefferies London Healthcare Conference 2025. My name is Roger Song, one of the senior analysts cover semicap biotech in the U.S. It is my pleasure to have my next fireside chat with Novavax.
Read More
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know
Published: November 11, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it worthwhile to examine what the stock has in store.
Read More
Novavax Q3 Earnings & Revenues Beat Estimates, '25 Sales View Raised
Published: November 07, 2025 by: Zacks Investment Research
Sentiment: Positive
NVAX exceeds third-quarter expectations, boosted by a Sanofi milestone payment. It lifts its 2025 sales outlook.
Read More
Novavax, Inc. (NVAX) Q3 2025 Earnings Call Transcript
Published: November 06, 2025 by: Seeking Alpha
Sentiment: Neutral
Novavax, Inc. ( NVAX ) Q3 2025 Earnings Call November 6, 2025 8:30 AM EST Company Participants John Jacobs - President, CEO & Director Ruxandra Draghia-Akli - Executive VP and Head of Research & Development James Kelly - Executive VP, CFO & Treasurer Conference Call Participants Nabeel Nissar - Jefferies LLC, Research Division Mayank Mamtani - B. Riley Securities, Inc., Research Division Eric Schmidt - Cantor Fitzgerald & Co., Research Division Christopher LoBianco - TD Cowen, Research Division Alec Stranahan - BofA Securities, Research Division Thomas Shrader - BTIG, LLC, Research Division Xun Lee - H.C.
Read More
Novavax (NVAX) Reports Q3 Loss, Beats Revenue Estimates
Published: November 06, 2025 by: Zacks Investment Research
Sentiment: Neutral
Novavax (NVAX) came out with a quarterly loss of $0.62 per share versus the Zacks Consensus Estimate of a loss of $1.08. This compares to a loss of $0.76 per share a year ago.
Read More
Investors Heavily Search Novavax, Inc. (NVAX): Here is What You Need to Know
Published: October 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it worthwhile to examine what the stock has in store.
Read More
Novavax Announces Progress on Sanofi Agreement
Published: September 30, 2025 by: PRNewsWire
Sentiment: Neutral
GAITHERSBURG, Md. , Sept. 30, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced progress on its collaboration and license agreement (CLA) with Sanofi regarding Novavax's Matrix-M® adjuvant.
Read More
Here's Why Novavax (NVAX) is a Strong Momentum Stock
Published: September 26, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Here is What to Know Beyond Why Novavax, Inc. (NVAX) is a Trending Stock
Published: September 25, 2025 by: Zacks Investment Research
Sentiment: Positive
Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
About Novavax, Inc. (NVAX)
- IPO Date 1995-12-05
- Website https://www.novavax.com
- Industry Biotechnology
- CEO John Charles Jacobs
- Employees 952